Arrivent Biopharma, Inc.
Clinical trials sponsored by Arrivent Biopharma, Inc., explained in plain language.
-
New hope for Hard-to-Treat cancers: experimental drug MRG007 enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called MRG007 in people with advanced solid tumors (like colorectal, gastric, or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors.…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New hope for rare lung cancer mutation: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called firmonertinib against two standard drugs (osimertinib or afatinib) as a first treatment for people with advanced non-small cell lung cancer that has certain rare gene changes (EGFR PACC mutations). About 480 participants worldwide will be random…
Phase: PHASE3 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC